Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review
Clémence Martin,1,2 Pierre-Régis Burgel,1,2 Nicolas Roche1,2 1AP-HP Centre, Hôpital Cochin, Service de Pneumologie, Paris, France; 2Université de Paris, Institut Cochin, INSERM UMR 1016, Paris, FranceCorrespondence: Nicolas RocheService de Pneumologie, Hôpital Cochin, 27 rue du Faubourg Saint Jacque...
Main Authors: | Martin C, Burgel PR, Roche N |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-08-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/inhaled-dual-phosphodiesterase-34-inhibitors-for-the-treatment-of-pati-peer-reviewed-fulltext-article-COPD |
Similar Items
-
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
by: Ferguson GT, et al.
Published: (2021-04-01) -
Emerging pharmaceutical therapies for COPD
by: Lakshmi SP, et al.
Published: (2017-07-01) -
Exacerbations of COPD
by: Pavord ID, et al.
Published: (2016-02-01) -
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
by: Dave Singh, et al.
Published: (2020-02-01) -
Beyond corticosteroids: future prospects in the management of inflammation in COPD
by: N. Roche, et al.
Published: (2011-09-01)